Valuation: Allergy Therapeutics plc

Market Cap 285M 381M 340M 314M 533M 36.18B 542M 3.78B 1.5B 18.96B 1.43B 1.4B 59.77B P/E 2026 *
-4.95x
P/E 2027 * -
Enterprise Value 329M 440M 393M 363M 616M 41.8B 626M 4.37B 1.73B 21.9B 1.65B 1.62B 69.04B EV / Sales 2026 *
5.5x
EV / Sales 2027 * -
Free-Float
11.23%
Yield 2026 *
-
Yield 2027 * -
1 week-5.26%
Current month-5.26%
1 month-5.26%
3 months-18.18%
6 months-58.72%
Current year-59.09%
1 week 4
Extreme 4
5
1 month 4
Extreme 4
5
Current year 4
Extreme 4
12.1
1 year 4
Extreme 4
12.1
3 years 1.26
Extreme 1.26
12.1
5 years 0.8
Extreme 0.8
40.5
10 years 0.8
Extreme 0.8
40.5
Manager TitleAgeSince
Chief Executive Officer 62 30/06/2009
Director of Finance/CFO - 10/08/2023
Corporate Officer/Principal - 30/04/2013
Director TitleAgeSince
Director/Board Member 62 10/06/2009
Chairman 75 03/01/2011
Director/Board Member 69 05/06/2017
Date Insider Type Main position Quantity % Market Cap. Importance
13/06/26 Free

Chief Financial Officer

2,300,000 0.0363%
12/03/26
ZQ Capital Ltd.
OthersCompany 150,925,926 2.4575%
12/03/26
ZQ Capital Ltd.
OthersCompany 1,893,776,143 30.8360%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-5.26%-43.04%+240.91% 381M
-2.54%+1.75%+56.75%+117.82% 1,165B
-1.42%+4.16%+36.73%+72.42% 645B
+0.16%+0.79%+24.91%+95.34% 504B
-0.31%+2.95%+39.36%+63.56% 380B
-1.34%+0.06%+65.81%+41.49% 363B
-0.68%+1.67%+22.07%+50.94% 297B
-1.20%+0.99%+2.26%+22.95% 269B
-1.79%+1.20%+48.41%+57.55% 237B
-0.73%-0.85%+28.47%+100.57% 195B
Average -0.85%+1.76%+28.17%+86.35% 405.59B
Weighted average by Cap. -1.15%+3.17%+40.78%+80.35%

Financials

2026 *2027 *
Net sales 59.9M 80.12M 71.55M 66.1M 112M 7.61B 114M 795M 315M 3.99B 301M 294M 12.56B -
Net income -55.7M -74.51M -66.53M -61.46M -104M -7.07B -106M -740M -293M -3.71B -280M -274M -11.68B -
Net Debt 44.2M 59.12M 52.8M 48.77M 82.69M 5.61B 84.06M 587M 232M 2.94B 222M 217M 9.27B -
Projected Income Statement - Annual - Allergy Therapeutics plc
Logo Allergy Therapeutics plc
Allergy Therapeutics plc is a United Kingdom-based international commercial biotechnology company. The Company is focused on the treatment and diagnosis of allergic disorders, including aluminum free immunotherapies that have the potential to cure disease. It sells proprietary and third-party products from its subsidiaries in nine European countries and via distribution agreements in an additional 10 countries. It sells both injectable and sublingual (oral) allergen-specific immunotherapies. Its pipeline of products in clinical development includes vaccines for grass, tree, house dust mite and peanut. Its therapies are traded under various brand names depending on the market, such as Pollinex Quattro, Polligoid and TA Graser Top. Its commercial products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics and Acarovac Plus. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA MPL, Trees MATA MPL, and VLP Peanut.
Employees
584
Date Price Change Volume
23/10/26 GBX 4.500 0.00% 4,347
22/10/26 GBX 4.500 0.00% 0
21/10/26 GBX 4.500 0.00% 2,071
20/10/26 GBX 4.500 0.00% 393,738
19/10/26 GBX 4.500 0.00% 150,249
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.0450GBP
Average target price
0.1300GBP
Spread / Average Target
+188.89%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Allergy Therapeutics plc